Clinical Trials Logo

Lymphoma, Malignant clinical trials

View clinical trials related to Lymphoma, Malignant.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02846584 Active, not recruiting - Clinical trials for Lymphoma, Large B-Cell, Diffuse

a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

Start date: July 2016
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to explore the sequential therapeutic effect and evaluate the safety of anti-CD19 or anti-CD20 CAR-T cells briging HSCT in the treatment of relapse/refractory B cell malignancies.

NCT ID: NCT02732275 Active, not recruiting - Clinical trials for Non-hodgkin Lymphoma

DS-3201b in Participants With Lymphomas

Start date: March 31, 2016
Phase: Phase 1
Study type: Interventional

DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research. Adults with non-Hodgkin lymphoma (NHL) might be able to join this study if their disease: - has come back after remission - is not responding to current treatment This study has three parts: 1. Dose Escalation is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. 2. Dose Expansion is to: - find out how effective DS-3201b is for rare types of NHL - collect additional safety data 3. Drug-Drug Interaction (DDI) Cohort (US Only) is to evaluate the effect of DS-3201b on the pharmacokinetics (PK) midazolam and digoxin when co-administered to patients with NHL